• Uterine leiomyosarcoma – the principles of diagnosis and treatment.
en To content

Uterine leiomyosarcoma – the principles of diagnosis and treatment.

HEALTH OF WOMAN. 2016.5(111):156–159 
 

Uterine leiomyosarcoma – the principles of diagnosis and treatment. 
 

Symonchuk E. V., Sharma N. A.

Shupyk National Medical Academy of Postgraduate Education, Kiev, Ukraine


The article presents data on the morphological features of uterine leiomyosarcoma; considered klinika, diagnostics, surgery to the treatment based on the patient’s age, adjuvant radiation and chemotherapy, follow-up.


Key words: uterine leiomyosarcoma, diagnosis, treatment.


REFERENCES

1. Bohman YV, Urmancheeva AF. 1996. Uterine sarcoma. St. Petersburg, Hippocrates:128.

2. Ulrich EA. 2013. Features of treatment of uterine sarcomas. Practical Oncology 14;2:127-134.

3. Lazareva NI, Kuznetsov VV, Zakharova TI. 2005. Sarcoma. Clinical Oncology: Guide for Physicians. M, Publishing House. Medicine:178-219.

4. Kohanevich EV. 2009. Cervical and endometrial pathology. Guidelines for doctors. Nizhyn: Gydromaks:324-327.

5. FIGO Committee on Gynecologic Oncology. FIGO staging for uterine sarcomas. 2009. J. Gynaecol. Obstet. 104:179.

6. George Demetri D, Margaret von Mehren, Robin Jones L. 2015. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J. Clin.Onkol. 62.4734.

7. Hensley ML, Maki R, Venkatraman E et al. 2002. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20:2824–2831. http://dx.doi.org/10.1200/JCO.2002.11.050; PMid:12065559

8. Hensley ML, Wathen K, Maki RG et al. 2011. 3-year follow-up ot SARC005: adjuvant treatment ot high risk primary uterine leiomyosarcoma with gemcitabine/ docetaxel, followed by doxorubicin. Connective Tissue Oncology Society Annual Meeting. Chicago:78.

9. Mahdavi A, Monk BJ, Ragazzo J et al. 2009. Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: a 20-year experience. J. Gynaecol. Cancer. 19:1080-1084. http://dx.doi.org/10.1111/IGC.0b013e3181acae50; PMid:19820372

10. Maki RG. 2007. Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Oncologist. Aug. 12(8):999-1006. http://dx.doi.org/10.1634/theoncologist.12-8-999

11. Morgan JA, Cesne ALe, Chawla SM et al. 2007. Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (L-sarcomas) after failure of prior anthracylines (A) and ifosfamide (I) Journal of Clinical Oncology. ASCO Annual Meeting Proceedings (Post-Meeting Edition). 25;18S (June 20 Supplement):10060.

12. Omura GA, Blessing JA, Major F et al. 1985. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynaecologic Oncology Group Study. J. Clin. Oncol. 3:1240-1245.

13. Petru E, Jonat W, Fink D, Kochli O. 2009. Praxisbuch Gynakologische Onklogie. Springer. Heidelberg:60-65.

14. Reed NS, Mangioni C, Malmstrom H et al. 2008. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organization for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Europ. J. Cancer. 44:808-818. http://dx.doi.org/10.1016/j.ejca.2008.01.019http://dx.doi.org/10.1016/j.ejca.2008.01.029

15. Sabelle Laure Ray-Coquard, Stefan Sleijfer, Saskia Litiиre et al. 2014. Pazopanib in uterine sarcoma (UtS): Review of two European Organisation for Research and Treatment of Cancer (EORTC) and GSK clinical trials 62043 and 62072 on pazopanib for soft tissue sarcoma (STS). .J. Clin. Oncol 32:5:s, (suppl; abstr 10579).

16. Sampath S, Schultheiss TE, Ryu JK et al. 2010. The role of adjuvant radiation in uterine sarcomas. J. Radiat. Oncol. Biol. Phys. 76:728-734. http://dx.doi.org/10.1016/j.ijrobp.2009.02.077; PMid:19700247

17. Sutton G, Blessing JA, Malfetano JH. 1996. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol. Oncol 62:226–229. http://dx.doi.org/10.1006/gyno.1996.0220; PMid:8751554